BioCentury
ARTICLE | Financial News

NASH company Akero raises $70M, plans Phase IIa trial

December 12, 2018 6:27 PM UTC

Akero Therapeutics Inc. (San Francisco, Calif.) raised $70 million in a series B round to move non-alcoholic steatohepatitis compound AKR-001 into a Phase IIa trial in mid-2019. The round was led by Janus Henderson Investors and included new investors Redmile Group, Boxer Capital, Cormorant Asset, BVF Partners, Rock Springs Captial and LifeSci Venture Partners as well as existing investors Apple Tree Partners, Atlas Venture, venBio Partners and Versant Ventures.

Akero emerged from stealth mode in June with $65 million in series A funds. President and CEO Andrew Cheng told BioCentury that the company has since been focused on building its team and preparing for an IND submission...

BCIQ Company Profiles

Akero Therapeutics Inc.